World's Best Scientists 2026 revealed!
I. Jolanda M. de Vries

I. Jolanda M. de Vries

D-Index & Metrics

Immunology

D-Index
83
Citations
22822
World Ranking
1462
National Ranking
54

I. Jolanda M. de Vries publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where I. Jolanda M. de Vries sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 235 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

I. Jolanda M. de Vries D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where I. Jolanda M. de Vries sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 83 D-Index — 71st percentile

71% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

I. Jolanda M. de Vries is affiliated with Radboud University in the Netherlands and has a significant body of work in medical research, particularly in the fields of immunology and oncology. Their research portfolio bridges core areas such as immunotherapy and immune responses, cancer immunotherapy and biomarkers, and immune cell function and interaction.

The main fields of study for de Vries include Medicine and Immunology and Microbiology, with a notable focus on the subfields of Immunology, Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, and Surgery. The emphasis on immunotherapy and cancer-related immune studies is evident throughout their publication record.

The scientist's recent publications include:

  • Lactate dehydrogenase: a marker of diminished antitumor immunity (2020, OncoImmunology)
  • Trial watch: Dendritic cell (DC)-based immunotherapy for cancer (2022, OncoImmunology)
  • The tumour microenvironment shapes dendritic cell plasticity in a human organotypic melanoma culture (2020, Nature Communications)
  • Subsets of CD1c+ DCs: Dendritic Cell Versus Monocyte Lineage (2020, Frontiers in Immunology)
  • Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients (2021, Journal of Allergy and Clinical Immunology)

The frequent venues where de Vries publishes work include:

  • Frontiers in Immunology
  • OncoImmunology
  • Nature Communications
  • Cancers
  • Journal for ImmunoTherapy of Cancer

Collaborations are a significant aspect of their research activities. Frequent co-authors include Mark A.J. Gorris, Carl G. Figdor, Gerty Schreibelt, Johannes Textor, and Georgina Flórez-Grau, reflecting interdisciplinary and extensive teamwork.

The work of de Vries spans important topics related to immune mechanisms and cancer, particularly:

  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • CAR-T cell therapy research
  • T-cell and B-cell Immunology
  • Immune cells in cancer
  • Immune Response and Inflammation

Best Publications

  • Dendritic cell immunotherapy: mapping the way

    Carl G Figdor;I Jolanda M de Vries;W Joost Lesterhuis;Cornelis J M Melief

  • Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy

    I Jolanda M de Vries;W Joost Lesterhuis;Jelle O Barentsz;Pauline Verdijk

  • Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting

    Paul J. Tacken;I. Jolanda M. de Vries;Ruurd Torensma;Carl G. Figdor

  • Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state

    I. Jolanda M. de Vries;Daniëlle J. E. B. Krooshoop;Nicole M. Scharenborg;W. Joost Lesterhuis

  • The C-type lectin DC-SIGN (CD209) is an antigen-uptake receptor for Candida albicans on dendritic cells.

    Alessandra Cambi;Karlijn Gijzen;I. Jolanda M. de Vries;Ruurd Torensma

  • Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics

    Stanleyson V. Hato;Andrea Khong;I. Jolanda M. de Vries;W. Joost Lesterhuis

  • Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

    Viggo F. van Tendeloo;Ann Van de Velde;Ann van Driessche;Nathalie Cools

  • Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients

    I. Jolanda M. de Vries;W. Joost Lesterhuis;Nicole M. Scharenborg;Linda P. H. Engelen

  • Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

    Jurjen Tel;Erik H.J.G. Aarntzen;Tetsuro Baba;Gerty Schreibelt

  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

    Kalijn F. Bol;Gerty Schreibelt;Winald R. Gerritsen;I. Jolanda M. de Vries

  • Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

    W. Joost Lesterhuis;Cornelis J.A. Punt;Stanleyson V. Hato;Dagmar Eleveld-Trancikova

  • Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production

    Friederike Meyer-Wentrup;Daniel Benitez-Ribas;Paul J. Tacken;Cornelis J. A. Punt

  • Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

    Gerty Schreibelt;Jurjen Tel;Kwinten H. E. W. J. Sliepen;Daniel Benitez-Ribas

  • Customizing poly(lactic-co-glycolic acid) particles for biomedical applications

    Edyta Swider;Olga Koshkina;Jurjen Tel;Luis J. Cruz

  • Migrating into the Tumor: a Roadmap for T Cells.

    Lieke L. van der Woude;Mark A.J. Gorris;Altuna Halilovic;Carl G. Figdor

  • 19)F MRI for quantitative in vivo cell tracking.

    Mangala Srinivas;Arend Heerschap;Eric T. Ahrens;Carl G. Figdor

  • The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.

    Gerty Schreibelt;Lieke J J Klinkenberg;Luis J Cruz;Paul J Tacken

  • Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?

    Joannes F M Jacobs;Stefan Nierkens;Carl G Figdor;I Jolanda M de Vries

  • Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors

    Joannes F.M. Jacobs;Albert J. Idema;Kalijn F. Bol;Stefan Nierkens

  • Dendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients

    Joannes F.M. Jacobs;Cornelis J.A. Punt;W. Joost Lesterhuis;Roger P.M. Sutmuller

Frequent Co-Authors

Carl G. Figdor
Carl G. Figdor Radboud University
Gerty Schreibelt
Gerty Schreibelt Radboud University
Gosse J. Adema
Gosse J. Adema Radboud University
Cornelis J. A. Punt
Cornelis J. A. Punt University of Amsterdam
Ruurd Torensma
Ruurd Torensma Radboud University
Winald R. Gerritsen
Winald R. Gerritsen Radboud University
Wim J.G. Oyen
Wim J.G. Oyen Humanitas University
Arend Heerschap
Arend Heerschap Radboud University
Otto C. Boerman
Otto C. Boerman Radboud University
Evelien Smits
Evelien Smits University of Antwerp

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in immunology opens diverse career opportunities, many of which overlap with nursing and healthcare fields. For those interested in advancing clinical expertise, programs such as accelerated RN to NP programs offer a streamlined pathway to becoming a nurse practitioner, allowing registered nurses to deepen their scope of practice quickly.

For nurses looking to specialize, transitioning between roles can be crucial. For example, if you are a family nurse practitioner (FNP) aiming to work in hospital settings, obtaining the FNP to acute care certification can open doors to acute and critical care environments.

Even those without a nursing background can enter the healthcare field through online ABSN programs for non nurses. These programs enable career changers to earn a Bachelor of Science in Nursing online, providing flexibility and accessibility.

Salary expectations also vary by location and specialization. Understanding how much does a DNP make across states can help in making informed decisions about career goals and potential financial rewards in advanced nursing roles.

Best Scientists Citing I. Jolanda M. de Vries

Trending Scientists

Recently Published Articles